Autoantibodies in systemic sclerosis

Autoimmunity Reviews

Volumn 12, Issue 3, 2013, Pages 340-354

  Mehra, Sonal ^a   Walker, Jennifer ^b   Patterson, Karen ^c   Fritzler, Marvin J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Autoantibodies; Autoantigens; Review; Scleroderma; Systemic sclerosis

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CENTROMERE ANTIBODY; CENTROMERE PROTEIN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ENDOTHELIAL CELL ANTIBODY; FIBRILLARIN ANTIBODY; FIBROBLAST ANTIBODY; HIGH MOBILITY GROUP PROTEIN ANTIBODY; HISTONE ANTIBODY; HLA DQB1 ANTIGEN; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NUCLEOPHOSMIN ANTIBODY; NUCLEOSOME ANTIBODY; NUMATRIN ANTIBODY; PEROXIREDOXIN 1; PLATELET DERIVED GROWTH FACTOR RECEPTOR ANTIBODY; PROTEIN ANTIBODY; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RNA POLYMERASE I ANTIBODY; RNA POLYMERASE II ANTIBODY; RNA POLYMERASE III ANTIBODY; SURVIVIN; TISSUE PLASMINOGEN ACTIVATOR; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; B LYMPHOCYTE; CELL NUCLEUS MEMBRANE; CENTROMERE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; NUCLEAR PORE COMPLEX; PATHOGENESIS; POLYMYOSITIS; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

AUTOANTIBODIES; HUMANS; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC;

EID: 84872387063     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.05.011     Document Type: Review

References (290)

1. Klein-Weigel P., Opitz C., Riemekasten G. Systemic sclerosis - a systematic overview: part 1 - disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. Vasa 2011, 40:6-19.
2. Opitz C., Klein-Weigel P.F., Riemekasten G. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. Vasa 2011, 40:20-30.
3. Barnes J., Mayes M.D. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012, 24:165-170.
4. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
5. Walker J.G., Pope J., Baron M., Leclercq S., Hudson M., Taillefer S., et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007, 26:1401-1409.
6. Hudson M., Fritzler M.J., Baron M. Systemic sclerosis: establishing diagnostic criteria. Medicine (Baltimore) 2010, 89:159-165.
7. Masi A.T., Rodnan G.P., Medsger T., Altman R.D., D'Angelo W.A., Fries J.F., et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
8. Fransen J., Johnson S.R., van den Hoogen F., Baron M., Allanore Y., Carreira P.E., et al. Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise with the ACR/EULAR working committee for classification criteria in systemic sclerosis. Arthritis Care Res (Hoboken) 2011, 10.
9. Akiyama Y., Ogawa F., Iwata Y., Komura K., Hara T., Muroi E., et al. Autoantibody against activating transcription factor-2 in patients with systemic sclerosis. Clin Exp Rheumatol 2009, 27:751-757.
10. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
11. Walker J.G., Fritzler M.J. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007, 19:580-591.
12. Graf S.W., Hakendorf P., Lester S., Patterson K., Walker J.G., Smith M.D., et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012, 15:102-109.
13. Fritzler M.J. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus 2006, 15:422-427.
14. Fritzler M.J., Fritzler M.L. Microbead-based technologies in diagnostic autoantibody detection. Expert Opin Med Diagn 2009, 3:81-89.
15. Fritzler M.J., Wiik A., Fritzler M.L., Barr S.G. The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 2003, 5:192-201.
16. Bossuyt X., Louche C., Wiik A. Standardisation in clinical laboratory medicine: an ethical reflection. Ann Rheum Dis 2008, 67:1061-1063.
17. Shoenfeld Y., Cervera R., Haass M., Kallenberg C., Khamashta M., Meroni P., et al. EASI - The European Autoimmunity Standardisation Initiative: a new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout Europe. Ann N Y Acad Sci 2007, 1109:138-144.
18. Okazaki K., Kawa S., Kamisawa T., Naruse S., Tanaka S., Nishimori I., et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol 2006, 41:626-631.
19. Kessenbrock K., Raijmakers R., Fritzler M.J., Mahler M. Synthetic peptides: the future of patient management in systemic rheumatic diseases?. Curr Med Chem 2007, 14:2831-2838.
20. Fritzler M.J. Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent. Autoimmun Highlights 2012, 10.1007/s13317-012-0030-7.
21. Mahler M., Ngo J., Schulte-Pelkum J., Luettich T., Fritzler M.J. Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther 2008, 10:R131.
22. Fritzler M.J. The antinuclear antibody (ANA) test: last or lasting gasp?. Arthritis Rheum 2011, 16:19-22.
23. Fritzler M.J. Autoantibody testing: current challenges and future opportunities. From Prediction to Prevention of Autoimmune Diseases 2011, 584-596. Pabst Science Publishers, Berlin. K. Conrad, E.K.L. Chan, M.J. Fritzler, R.L. Humbel, P.L. Meroni, Y. Shoenfeld (Eds.).
24. Ceribelli A., Satoh M., Chan E.K. A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis. Arthritis Res Ther 2012, 14:R128.
25. Mahler M., Fritzler M.J. Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci 2010, 1183:267-287.
26. Mahler M., Binder W.L., Fritzler M.J. Recent advances in peptide resolved diagnostics of systemic autoimmune diseases. From Prediction to Prevention of Autoimmune Diseases 2011, 598-625. Pabst Science Publishers, Berlin. K. Conrad, E.K.L. Chan, M.J. Fritzler, R.L. Humbel, P.L. Meroni, Y. Shoenfeld (Eds.).
27. Perez-Bravo F., Carrasco E., Echiburu B., Maliqueo M., Diaz J., Sir-Petermann T. Serological markers of autoimmunity in pregnant women with polycystic ovary syndrome: a pilot study. Gynecol Endocrinol 2010, 26:889-893.
28. Op De B.K., Vermeersch P., Verschueren P., Westhovens R., Marien G., Blockmans D., et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev 2011, 10:801-808.
29. Meheus L., Van Venrooij W.J., Wiik A., Charles P.J., Tzioufas A.G., Meyer O., et al. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear antibodies in connective tissue disorders. Clin Exp Rheumatol 1999, 17:205-214.
30. Bonroy C., Van P.J., Smith V., Van S.K., Mimori T., Deschepper E., et al. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods 2012, 379:53-60.
31. Op De B.K., Vermeersch P., Verschueren P., Westhovens R., Marien G., Blockmans D., et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev Feb 23 2012, [Electronic publication ahead of print].
32. Fritzler M.J., Fritzler M.L. The emergence of multiplexed technologies as diagnostic platforms in systemic autoimmune diseases. Curr Med Chem 2006, 13:2503-2512.
33. Mierau R., Moinzadeh P., Riemekasten G., Melchers I., Meurer M., Reichenberger F., et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011, 13:R172.
34. Bunn C.C., Denton C.P., Shi-Wen X., Knight C., Black C.M. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998, 37:15-20.
35. Jacobsen S., Halberg P., Ullman S., Van Venrooij W.J., Hoier-Madsen M., Wilk A., et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998, 37:39-45.
36. Meyer O.C., Fertig N., Lucas M., Somogyi N., Medsger T.A. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007, 34:104-109.
37. Hamaguchi Y., Hasegawa M., Fujimoto M., Matsushita T., Komura K., Kaji K., et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008, 158:487-495.
38. Denton C.P., Krieg T., Guillevin L., Schwierin B., Rosenberg D., Silkey M., et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis 2012, 71:718-721.
39. Wiik A.S., Hoier-Madsen M., Forslid J., Charles P., Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010, 35:276-290.
40. Mariz H.A., Sato E.I., Barbosa S.H., Rodrigues S.H., Dellavance A., Andrade L.E. ANA HEp-2 pattern is a critical parameter for discriminating ANA-positive healthy individuals and patietns with autoimmune rheumatic diseases. Arthritis Rheum 2011, 63:191-200.
41. Senecal J.L., Henault J., Raymond Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol 2005, 32:1643-1649.
42. Senecal J.L., Dieudé M., Koenig M. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7:588-593.
43. Moser J.J., Fritzler M.J., Rattner J.B. Primary ciliogenesis defects are associated with human astrocytoma/glioblastoma cells. BMC Cancer 2009, 9:448.
44. Steen V.D. The many faces of scleroderma. Rheum Dis Clin North Am 2008, 34:1-15.
45. Van Hoof A., Frischmeyer P.A., Dietz H.C., Parker R. Exosome-mediated recognition and degradation of mRNAs lacking a termination codon. Science 2002, 295:2262-2264.
46. Hildebrandt S., Jackh G., Weber S., Peter H.H. A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies. Rheumatol Int 1993, 12:231-234.
47. Tan E.M. Antinuclear antibodies in scleroderma. Int J Dermatol 1981, 20:569-573.
48. Nakamura R.M., Tan E.M. Recent advances in laboratory tests and the significance of autoantibodies to nuclear antigens in systemic rheumatic diseases. Clin Lab Med 1986, 6:41-53.
49. Douvas A.S., Achten M., Tan E.M. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979, 254:10514-10522.
50. Shero J.H., Bordwell B., Rothfield N.F., Earnshaw W.C. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 1986, 231:737-740.
51. Tervaert J.W., van der Woude F.J., Fauci A.S., Ambrus J.L., Velosa J., Keane W.F., et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989, 149:2461-2465.
52. Walker U.A., Tyndall A., Czirjak L., Denton C.P., Farge B.D., Kowal-Bielecka O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base. Ann Rheum Dis 2007, 66:754-763.
53. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002, 81:139-153.
54. Reveille J.D., Solomon D.H. The American College of Rheumatology Ad hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003, 49:399-412.
55. Mahler M., Silverman E.D., Schulte-Pelkum J., Fritzler M.J. Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality?. Autoimmun Rev 2010, 9:756-760.
56. Tamby M.C., Servettaz A., Guilpain P., Tamas N., Berezne A., Batteux F., et al. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis. Clin Immunol 2007, 123:82-88.
57. Tamby M.C., Bussone G., Mouthon L. Antitopoisomerase 1 antibodies in systemic sclerosis: how to improve the detection?. Ann N Y Acad Sci 2007, 1109:221-228. [8].
58. Allcock R.J., Forrest I., Corris P.A., Crook P.R., Griffiths I.D. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004, 43:596-602.
59. Reveille J.D., Fischbach M., McNearney T., Friedman A.W., Aguilar M.B., Lisse J., et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001, 30:332-346.
60. Reveille J.D., Durban E., MacLeod-St.Clair M.J., Goldstein R., Moreda R., Altman R.D., et al. Association of amino acid sequences in the HLA-DQB1 first domain with the antitopoisomerase I. Autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992, 90:973-980.
61. Kuwana M., Kaburaki J., Okano Y., Inoko H., Tsuji K. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest 1993, 92:1296-1301.
62. Hildebrandt S., Weiner E., Senecal J.L., Noell S., Daniels L., Earnshaw W.C., et al. The IgG, IgM, and IgA isotypes of anti-topoisomerase I and anticentromere autoantibodies. Arthritis Rheum 1990, 33:724-727.
63. Mahler M., Blüthner M., Pollard K.M. Advances in B-cell epitope analysis of autoantigens in connective tissue diseases. Clin Immunol 2003, 107:65-79.
64. Mukai M., Sagawa A., Atsumi T., Jodo S., Amasaki Y., Nakabayashi T., et al. 3 cases of anti-Scl-70 (Topoisomerase I) antibody associated with central nervous system lupus without renal disorder. J Rheumatol 1993, 20:1594-1597.
65. Gussin H.A., Ignat G.P., Varga J., Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:376-383.
66. Czompoly T., Simon D., Czirjak L., Nemeth P. Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 2009, 8:692-697.
67. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich É., Goulet J.R., et al. Predicting mortality in systemic sclerosis - analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002, 81:154-167.
68. Hesselstrand R., Scheja A., Shen G.Q., Wiik A., Åkesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 2003, 42:534-540.
69. Castro S.V., Jimenez S.A. Biomarkers in systemic sclerosis. Biomark Med 2010, 4:133-147.
70. Cepeda E.J., Reveille J.D. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004, 16:723-732.
71. Hu P.Q., Fertig N., Medsger T.A., Wright T.A. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003, 48:1363-1373.
72. Radic M., Martinovic K.D., Ljutic D. The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis. Clin Exp Rheumatol 2006, 24:407-412.
73. Nishijima C., Sato S., Hasegawa M., Nagaoka T., Hirata A., Komatsu K., et al. Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology (Oxford) 2001, 40:406-409.
74. Rothfield N., Kurtzman S., Vazques-Abad D., Charron C., Daniels L., Greenberg B. Association of anti-topoisomerase I with cancer. Arthritis Rheum 1992, 35:724.
75. Derk C.T., Sakkas L.I., Rasheed M., Artlett C., Jimenez S.A. Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol 2003, 30:1994-1996.
76. Kuwana M., Kaburaki J., Mimori T., Kawakami Y., Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000, 43:1074-1084.
77. Henault J., Robitaille G., Senecal J.L., Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006, 54:963-973.
78. Arcand J., Robitaille G., Koenig M., Senecal J.L., Raymond Y. Heparin inhibits the interaction of DNA topoisomerase I (topo-I)/anti-topo-I immune complexes with heparan sulfate on dermal fibroblasts. Arthritis Rheum 2012, 10.1002/art.33484.
79. Fritzler M.J., Rattner J.B., Luft L.M., Edworthy S.M., Casiano C.A., Peebles C., et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2010, 10:194-200.
80. Mahler M., You D., Baron M., Taillefer S.S., Hudson M., Fritzler M.J. Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clin Chim Acta 2011, 412:1937-1943.
81. Damoiseaux J., Boesten K., Giesen J., Austen J., Tervaert J.W. Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens. Ann N Y Acad Sci 2005, 1050:340-347.
82. Pottel H., Wiik A., Locht H., Gordon T., Roberts-Thomson P., Abraham D., et al. Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoantibodies in connective tissue disorders. Clin Exp Rheumatol 2004, 22:579-588.
83. Albon S., Bunn C., Swana G., Karim Y. Performance of a multiplex assay compared to enzyme and precipitation methods for anti-ENA testing in systemic lupus and systemic sclerosis. J Immunol Methods 2011, 365:126-131.
84. Gilburd B., Abu-Shakra M., Shoenfeld Y., Giordano A., Bocci E.B., delle Monache F., et al. Autoantibodies profile in the sera of patients with Sjogren's syndrome: the ANA evaluation--a homogeneous, multiplexed system. Clin Dev Immunol 2004, 11:53-56.
85. Mahler M., Maes L., Blockmans D., Westhovens R., Bossuyt X., Riemekasten G., et al. Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther 2010, 12:R99.
86. Hudson M., Mahler M., Pope J., You D., Tatibouet S., Steele R., et al. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012, 39:787-794.
87. Reveille J.D. The genetic basis of autoantibody production. Autoimmun Rev 2006, 5:389-398.
88. Sato H., Lagan A.L., Alexopoulou C., Vassilakis D.A., Ahmad T., Pantelidis P., et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 2004, 50:558-564.
89. Fritzler M.J., Kinsella T.D. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980, 69:520-525.
90. Moroi Y., Peebles C., Fritzler M.J., Steigerwald J., Tan E.M. Autoantibody to centromere (Kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A 1980, 77:1627-1631.
91. Tan E.M., Rodnan G.P., Garcia I., Moroi Y., Fritzler M.J., Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980, 23:617-625.
92. Hanke K., Becker M.O., Brueckner C.S., Meyer W., Janssen A., Schlumberger W., et al. Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol 2010, 37:2548-2552.
93. Gliddon A.E., Dore C.J., Dunphy J., Betteridge Z., McHugh N.J., Maddison P.J. Antinuclear antibodies and Clinical Associations in a British Cohort with limited cutaneous systemic sclerosis. J Rheumatol 2011, 38:702-705.
94. Mitri G.M., Lucas M., Fertig N., Steen V.D., Medsger T.A. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003, 48:203-209.
95. Akiyama Y., Tanaka M., Takeishi M., Adachi D., Mimori A., Suzuki T. Clinical, serological and genetic study in patients with CREST syndrome. Intern Med 2000, 39:451-456.
96. Miyawaki S., Asanuma H., Nishiyama S., Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005, 32:1488-1494.
97. Mourelatos Z. MicroRNAs: biology and roles in neurodegeneration and brain tumours. Introduction and historical background. Brain Pathol 2008, 18:110-112.
98. Makinen D., Fritzler M.J., Davis P., Sherlock S. Anticentromere antibodies in primary biliary cirrhosis. Arthritis Rheum 1983, 26:914-917.
99. Bernstein R.M., Callender M.E., Neuberger J.M., Hughes G.R.V., Williams R. Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 1982, 41:612-614.
100. Marasini B., Gagetta M., Rossi V., Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 2001, 60:1046-1049.
101. Rigamonti C., Shand L.M., Feudjo M., Bunn C.C., Black C.M., Denton C.P., et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006, 55:388-394.
102. Furuta K., Hildebrandt B., Matsuoka S., Kiyosawa K., Reimer G., Luderschmidt C., et al. Immunological characterization of heterochromatin protein p25β autoantibodies and relationship with centromere autoantibodies and pulmonary fibrosis in systemic scleroderma. J Mol Med 1998, 76:54-60.
103. Gelber A.C., Pillemer S.R., Baum B.J., Wigley F.M., Hummers L.K., Morris S., et al. Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma. Ann Rheum Dis 2006, 65:1028-1032.
104. Pillemer S.R., Casciola-Rosen L., Baum B.J., Rosen A., Gelber A.C. Centromere protein C is a target of autoantibodies in Sjogren's syndrome and is uniformly associated with antibodies to Ro and La. J Rheumatol 2004, 31:1121-1125.
105. Hamdouch K., Rodriguez C., Perez-Venegas J., Rodriguez I., Astola A., Ortiz M., et al. Anti-CENPI autoantibodies in scleroderma patients with features of autoimmune liver diseases. Clin Chim Acta 2011, 412:2267-2271.
106. Kuwana M., Kaburaki J., Mimori T., Tojo T., Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993, 91:1399-1404.
107. Okano Y., Steen V.D., Medsger T.A. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993, 119:1005-1013.
108. Nguyen B., Mayes M.D., Arnett F.C., Del J.D., Reveille J.D., Gonzalez E.B., et al. HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011, 63:530-534.
109. Santiago M., Baron M., Hudson M., Burlingame R.W., The Canadian Scleroderma Research Group, Fritzler M.J. Antibodies to RNA polymerase III in systemic sclerosis as detected by an ELISA. J Rheumatol 2007, 34:1528-1534.
110. Meyer O., De C.L., Nicaise-Roland P., Cabane J., Tubach F., Dieude P., et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010, 37:125-130.
111. Airo' P., Ceribelli A., Cavazzana I., Taraborelli M., Zingarelli S., Franceschini F. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011, 38:1329-1334.
112. Satoh T., Ishikawa O., Ihn H., Endo H., Kawaguchi Y., Sasaki T., et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology (Oxford) 2009, 48:1570-1574.
113. Nikpour M., Hissaria P., Byron J., Sahhar J., Micallef M., Paspaliaris W., et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011, 13:R211.
114. Yamasaki Y., Honkanen-Scott M., Hernandez L., Ikeda K., Barker T., Bubb M.R., et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 2006, 54:3051-3056.
115. Parker J.C., Burlingame R.W., Webb T.T., Bunn C.C. Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology (Oxford) 2008, 47:976-979.
116. Satoh M., Ajmani A.K., Ogasawara T., Langdon J.J., Hirakata M., Wang J., et al. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 1994, 94:1981-1989.
117. Hesselstrand R., Scheja A., Wuttge D.M. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol 2012, 41:39-43.
118. Ceribelli A., Cavazzana I., Airo P., Franceschini F. Anti-RNA polymerase III antibodies as a risk marker for early gastric antral vascular ectasia (GAVE) in systemic sclerosis. J Rheumatol 2010, 37:1544.
119. Wenzel J. Scleroderma and malignancy. Mechanisms of interrelationship. Eur J Dermatol 2002, 12:296-300.
120. Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008, 101:59-62.
121. Shah A.A., Rosen A., Hummers L., Wigley F., Casciola-Rosen L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010, 62:2787-2795.
122. Honma M., Komatsu S., Igawa S., Murakami M., Iizuka H. Rapidly progressive systemic sclerosis associated with breast carcinoma: Report of a case with anti-RNA polymerase III antibody. J Dermatol 2012, 39:574-576.
123. van Eenennaam H., Vogelzangs J.H.P., Lugtenberg D., van den Hoogen F.H.J., Van Venrooij W.J., Pruijn G.J.M. Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. Arthritis Rheum 2002, 46:3266-3272.
124. Okano Y., Medsger T.A. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990, 33:1822.
125. Falkner D., Wilson J., Medsger T.A., Morel P.A. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum 1998, 41:74-80.
126. van Eenennaam H., Vogelzangs J.H.P., Bisschops L., Te Boome L.C.J., Seelig H.P., Renz M., et al. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 2002, 130:532-540.
127. Ceribelli A., Cavazzana I., Franceschini F., Airo P., Tincani A., Cattaneo R., et al. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 2010, 37:2071-2075.
128. Fischer A., Pfalzgraf F.J., Feghali-Bostwick C.A., Wright T.M., Curran-Everett D., West S.G., et al. Anti-Th/To-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006, 33:1600-1605.
129. Smith C.M., Steitz J.A. Sno storm in the nucleolus: new roles for myriad small RNPs. Cell 1997, 89:669-672.
130. Tormey V.J., Bunn C.C., Denton C.P., Black C.M. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2002, 40:1157-1162.
131. Aggarwal R., Lucas M., Fertig N., Oddis C.V., Medsger T.A. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009, 60:1112-1118.
132. Arnett F.C., Reveille J.D., Goldstein R., Pollard K.M., Leaird K., Smith E.A., et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serological and clinical analysis. Arthritis Rheum 1996, 39:1151-1160.
133. Sharif R., Fritzler M.J., Mayes M.D., Gonzalez E.B., McNearney T.A., Draeger H., et al. Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol 2011, 38:1622-1630.
134. Benavente R., Schmidt-Zachmann M.S., Hugle-Dorr B., Reimer G., Rose K.M., Scheer U. Identification and definition of nucleolus-related fibrillar bodies in micronucleated cells. Exp Cell Res 1988, 178:518-523.
135. Reimer G. Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1990, 16:169-183.
136. Villalta D., Morozzi G., Tampoia M., Alpini C., Brusca I., Salgarolo V., et al. Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis. Clin Chim Acta 2010, 411:710-713.
137. Havarinasab S., Pollard K.M., Hultman P. Gold- and silver-induced murine autoimmunity-requirement for cytokines and CD28 in murine heavy metal-induced autoimmunity. Clin Exp Immunol 2009, 155:567-576.
138. Pollard K.M., Hultman P., Kono D.H. Toxicology of autoimmune diseases. Chem Res Toxicol 2010, 23:455-466.
139. Arnett F.C., Fritzler M.J., Ahn C., Holian A. Urinary mercury levels in patients with autoantibodies to U3-RNP (fibrillarin). J Rheumatol 2000, 27:405-410.
140. Yang J.M., Hildebrandt B., Luderschmidt C., Pollard K.M. Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex. Arthritis Rheum 2003, 48:210-217.
141. Wassarman K.M., Steitz J.A. The low-abundance U11 and U12 small nuclear ribonucleoproteins (snRNPs) interact to form a two-snRNP complex. Mol Cell Biol 1992, 12:1276-1285.
142. Fertig N., Domsic R.T., Rodriguez-Reyna T., Kuwana M., Lucas M., Medsger T.A., et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009, 61:958-965.
143. Ochs R.L., Lischwe M.A., O'Leary P., Busch H. Localization of nucleolar phosphoproteins B23 and C23 during mitosis. Exp Cell Res 1983, 146:139-149.
144. Li X., McNeilage J., Whittingham S. Autoantibodies to the major nucleolar phosphoprotein B23 define a novel subset of patients with anticardiolipin antibodies. Arthritis Rheum 1989, 32:1165-1169.
145. Ulanet D.B., Wigley F.M., Gelber A.C., Rosen A. Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum 2003, 49:85-92.
146. Imai H., Kiyosawa K., Chan E.K.L., Tan E.M. Autoantibodies in viral hepatitis-related hepatocellular carcinoma. Intervirology 1993, 35:73-85.
147. Fox R.I., Chan E.K.L., Kang H.I. Laboratory evaluation of patients with Sjögren's syndrome. Clin Biochem 1992, 25:213-222.
148. Ben-Chetrit E. Anti Ro/La antibodies and their clinical association. Isr J Med Sci 1997, 33:251-253.
149. Schulte-Pelkum J., Fritzler M., Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009, 8:632-637.
150. Ben-Chetrit E., Chan E.K.L., Sullivan K.F., Tan E.M. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med 1988, 167:1560-1571.
151. Racanelli V., Prete M., Musaraj G., Dammacco F., Perosa F. Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev 2011, 10:503-508.
152. Ben-Chetrit E. The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies. Br J Rheumatol 1993, 32:396-402.
153. Hervier B., Rimbert M., Colonna F., Hamidou M.A., Audrain M. Clinical significance of anti-Ro/SSA-52 kDa antibodies-a retrospective monocentric study. Rheumatology (Oxford) 2009, 48:964-967.
154. Defendenti C., Atzeni F., Spina M.F., Grosso S., Cereda A., Guercilena G., et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011, 10:150-154.
155. Dugar M., Cox S., Limaye V., Gordon T.P., Roberts-Thomson P.J. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 2010, 86:79-82.
156. Hudson M., Pope J., Mahler M., Tatibouet S., Steele R., Baron M., et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 2012, 14:R50.
157. Peene I., Meheus L., Veys E.M., De K.F. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis 2002, 61:1090-1094.
158. Fujimoto M., Shimozuma M., Yazawa N., Kubo M., Ihn H., Sato S., et al. Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis 1997, 56:667-670.
159. Tarn W.Y., Steitz J.A. Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge. Trends Biochem Sci 1997, 22:132-137.
160. Keith M.P., Moratz C., Tsokos G.C. Anti-RNP immunity: implications for tissue injury and the pathogenesis of connective tissue disease. Autoimmun Rev 2007, 6:232-236.
161. Babst M. GGAing ubiquitin to the endosome. Nat Cell Biol 2004, 6:175-177.
162. Ihn H., Yamane K., Yazawa N., Kubo M., Fujimoto M., Sato S., et al. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol 1999, 117:383-387.
163. Nihtyanova S.I., Denton C.P. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010, 6:112-116.
164. Lundberg I., Hedfors E. Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol 1991, 18:1511-1519.
165. Jablonska S., Blaszczyk M. Scleroderma overlap syndromes. Adv Exp Med Biol 1999, 455:85-92. [85-92].
166. Kasukawa R. Mixed connective tissue disease. Intern Med 1999, 38:386-393.
167. Asano Y., Ihn H., Yamane K., Kubo M., Tamaki K. The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol 2003, 120:204-210.
168. Borkowski A., Gyling M., Muquardt C., Body J.J., Leclercq G. Estrogen-like activity of a subpopulation of natural antiestrogen receptor autoantibodies in man. Endocrinology 1991, 128:3283-3292.
169. Burlingame R.W., Love W.E., Wang B.-C., Hamlin R., Xuong N.-H., Moudrianakis E.N. Crystallographic structure of the octameric histone core of the nucleosome at a resolution of 3.3 A. Science 1985, 228:546-553.
170. Gomez-Puerta J.A., Burlingame R.W., Cervera R. Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun Rev 2008, 7:606-611.
171. Amoura Z., Piette J.-C., Bach J.-F., Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999, 42:833-843.
172. Amoura Z., Koutouzov S., Chabre H., Cacoub P., Amoura I., Musset L., et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases - antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000, 43:76-84.
173. Sato S., Kodera M., Hasegawa M., Fujimoto M., Takehara K. Antinucleosome antibody is a major autoantibody in localized scleroderma. Br J Dermatol 2004, 151:1182-1188.
174. Rubin R.L., Fritzler M.J. Antibodies to histones and nucleosome-related antigens. Dubois' lupus erythematosus 2007, 464-486. Lippincott Williams & Wilkins, Philadelphia. D.J. Wallace, B.H. Hahn (Eds.).
175. Kohlstaedt L.A., Cole R.D. Specific interaction between H1 histone and high mobility protein HMG1. Biochemistry 1994, 33:570-575.
176. Martin L., Pauls J.D., Ryan J.P., Fritzler M.J. Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone. Ann Rheum Dis 1993, 52:780-784.
177. Ayer L.M., Senécal J.-L., Martin L., Dixon G.H., Fritzler M.J. Antibodies to high mobility group (HMG) proteins in systemic sclerosis. J Rheumatol 1994, 21:2071-2075.
178. Pisetsky D.S., Erlandsson-Harris H., Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008, 10:209.
179. Urbonaviciute V., Voll R.E. HMGB1 represents a potential marker of disease activity and novel therapeutic target in SLE. J Intern Med 2011, 270:309-318.
180. Dupire G., Nicaise C., Gangji V., Soyfoo M. Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjogren's syndrome. Scand J Rheumatol 2012, 41:120-123.
181. Yoshizaki A., Komura K., Iwata Y., Ogawa F., Hara T., Muroi E., et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2009, 29:180-189.
182. Tzioufas A.G., Boumba V.A., Seferiadis C., Tsolas O., Moutsopoulos H.M. Autoantibodies to HMG-17 nucleosomal protein in autoimmune rheumastic diseases. Correlation with systemic lupus erythematosus clinical activity and with antibodies to double-stranded DNA. Arthritis Rheum 1993, 36:955-961.
183. Lees-Miller S.P., Meek K. Repair of DNA double strand breaks by non-homologous end joining. Biochimie 2003, 85:1161-1173.
184. Takeda Y., Dynan W.S. Autoantibodies against DNA double-strand break repair proteins. Front Biosci 2001, 6:D1412-D1422.
185. Belizna C., Henrion D., Beucher A., Lavigne C., Ghaali A., Levesque H. Anti-Ku antibodies: clinical, genetic and diagnostic insights. Autoimmun Rev 2010, 9:691-694.
186. Rozman B., Cucnik S., Sodin-Semrl S., Czirjak L., Varju C., Distler O., et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 2008, 67:1282-1286.
187. Reeves W.H. Antibodies to the p70/p80 (Ku) antigens in systemic lupus erythematosus. Rheum Dis Clin North Am 1992, 18:391-414.
188. Troyanov Y., Targoff I.N., Tremblay J.L., Goulet J.R., Raymond Y., Senécal J.L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005, 84:231-249.
189. Sordet C., Goetz J., Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 2006, 73:646-654.
190. Schild-Poulter C., Su A., Shih A., Kelly O.P., Fritzler M.J., Goldstein R., et al. Association of autoantibodies to Ku and DNA repair proteins in connective tissue diseases. Rheumatology (Oxford) 2007, 47:165-171.
191. Brouwer R., Egberts W.V., Hengstman G.J.D., Rajimakers R., van Engelen B.G.M., Seelig H.P., et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002, 4:134-138.
192. Mahler M., Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insiights. Autoimmun Rev 2007, 6:432-437.
193. Mahler M., Fritzler M.J. The changing landscape of the clinical value of the PM/Scl autoantibody system. Arthritis Res Ther 2009, 11:106.
194. Mahler M., Raijmakers R., Dahnrich C., Bluthner M., Fritzler M.J. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005, 7:R704-R713.
195. Mahler M., Fritzler M.J. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?. Autoimmun Rev 2008, 8:373-378.
196. Raijmakers R., Renz M., Wiemann C., Egberts W.V., Seelig H.P., Van Venrooij W.J., et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 2004, 50:565-569.
197. Hanke K., Bruckner C.S., Dahnrich C., Huscher D., Komorowski L., Meyer W., et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 2009, 11:R22.
198. Chan E.K.L., Imai H., Hamel J.C., Tan E.M. Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolar organizer region auotantigen NOR-90 and ribosomal RNA transcription upstream binding factor. J Exp Med 1991, 174:1239-1244.
199. Imai H., Fritzler M.J., Neri R., Bombardieri S., Tan E.M., Chan E.K.L. Immunocytochemical localization of two Mr forms of human NOR-90 (Upstream Binding Factor) and associated antigens reactive with autoimmune sera. Mol Biol Rep 1994, 19:115-124.
200. Dagher J.H., Scheer U., Voit R., Grummt I., Lonzetti L., Raymond Y., et al. Autoantibodies to NOR 90/hUBF: longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response. J Rheumatol 2002, 29:1543-1547.
201. Fritzler M.J., von Muhlen C.A., Toffoli S.M., Staub H.L., Laxer R.M. Autoantibodies to the nucleolar organizer antigen NOR-90 in children with systemic rheumatic diseases. J Rheumatol 1995, 22:521-524.
202. Fujii T., Mimori T., Akizuki M. Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 1996, 39:1313-1318.
203. Whitehead C.M., Fritzler M.J., Rattner J.B. The relationship of ASE-1 and NOR-90 in autoimmune sera. J Rheumatol 1998, 25:2126-2130.
204. Enarson P., Rattner J.B., Ou Y., Miyachi K., Horigome T., Fritzler M.J. Autoantigens of the nuclear pore complex. J Mol Med 2004, 82:423-433.
205. McKeon F.D., Tuffanelli D.L., Fukuyama K., Kirschner M.W. Autoimmune response directed against conserved determinants of nuclear envelope proteins in a patient with linear scleroderma. Proc Natl Acad Sci U S A 1983, 80:4374-4378.
206. Ou Y., Enarson P., Rattner J.B., Barr W., Fritzler M.J. The nuclear pore complex protein Tpr is a common autoantigen in sera that demonstrate nuclear envelope staining by indirect immunofluorescence. Clin Exp Immunol 2004, 136:379-387.
207. Svegliati S., Cancello R., Sambo P., Luchetti M., Paroncini P., Orlandini G., et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005, 280:36474-36482.
208. Classen J.F., Henrohn D., Rorsman F., Lennartsson J., Lauwerys B.R., Wikstrom G., et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009, 60:1137-1144.
209. Loizos N., Lariccia L., Weiner J., Griffith H., Boin F., Hummers L., et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 2009, 60:1145-1151.
210. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
211. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Sirinian C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010, 49:271-280.
212. Daoussis D., Liossis S.N., Yiannopoulos G., Andonopoulos A.P. B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol 2011, 214013.
213. Balada E., Simeon-Aznar C.P., Ordi-Ros J., Rosa-Leyva M., Selva-O'Callaghan A., Pardos-Gea J., et al. Anti-PDGFR-{alpha} antibodies measured by non-bioactivity assays are not specific of systemic sclerosis. Ann Rheum Dis 2008, 67:1027-1029.
214. Kurasawa K., Arai S., Owada T., Maezawa R., Kumano K., Fukuda T. Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus. Mod Rheumatol 2010, 20:458-465.
215. Dragun D., Distler J.H., Riemekasten G., Distler O. Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum 2009, 60:907-911.
216. Negi V.S., Tripathy N.K., Misra R., Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998, 25:462-466.
217. Wusirika R., Ferri C., Marin M., Knight D.A., Waldman W.J., Ross P., et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis - a study of indirect immunofluorescent and Western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 2003, 120:596-606.
218. Riccieri V., Germano V., Alessandri C., Vasile M., Ceccarelli F., Sciarra I., et al. More severe nailfold capillaroscopy findings and anti-endothelial cell antibodies. Are they useful tools for prognostic use in systemic sclerosis?. Clin Exp Rheumatol 2008, 26:992-997.
219. Sgonc R., Gruschwitz M.S., Dietrich H., Recheis H., Gershwin M.E., Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785-792.
220. Mihai C., Tervaert J.W. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis 2010, 69:319-324.
221. Tamby M.C., Chanseaud Y., Humbert M., Fermanian J., Guilpain P., Garcia-de-la-Pena-Lefebvre P., et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005, 60:765-772.
222. Servettaz A., Tamby M.C., Guilpain P., Reinbolt J., Garcia de la Pena-Lefebvre P., Allanore Y., et al. Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). Clin Immunol 2006, 120:212-219.
223. Ahmed S.S., Tan F.K., Arnett F.C., Jin L., Geng Y.J. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006, 54:2250-2262.
224. De la Peña-Lefebvre P.G., Chanseaud Y., Tamby M.C., Reinbolt J., Batteux F., Allanore Y., et al. IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. Clin Immunol 2004, 111:241-251.
225. Fineschi S., Goffin L., Rezzonico R., Cozzi F., Dayer J.M., Meroni P.L., et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 2008, 58:3913-3923.
226. Chizzolini C., Raschi E., Rezzonico R., Testoni C., Mallone R., Gabrielli A., et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002, 46:1602-1613.
227. Terrier B., Tamby M.C., Camoin L., Guilpain P., Berezne A., Tamas N., et al. Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 2010, 69:428-433.
228. Tamby M.C., Humbert M., Guilpain P., Servettaz A., Dupin N., Christner J.J., et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006, 28:799-807.
229. Avouac J., Airo P., Dieude P., Caramaschi P., Tiev K., Diot E., et al. Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients. J Rheumatol 2010, 37:608-614.
230. Assassi S., Fritzler M.J., Arnett F.C., Norman G.L., Shah K.R., Gourh P., et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009, 36:2250-2256.
231. Gupta R.C., Seibold J.R., Krishnan M.R., Steigerwald J.C. Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis. Clin Exp Immunol 1984, 58:68-76.
232. Cavazzana I., Ceribelli A., Taraborelli M., Fredi M., Norman G., Tincani A., et al. Primary biliary cirrhosis-related autoantibodies in a large cohort of Italian patients with systemic sclerosis. J Rheumatol 2011, 38:2180-2185.
233. Skare T.L., Nisihara R.M., Haider O., Azevedo P.M., Utiyama S.R. Liver autoantibodies in patients with scleroderma. Clin Rheumatol 2011, 30:129-132.
234. Casari S., Haeney M., Farrand S., Herrick A. Antineutrophil cytoplasmic antibodies - a "Red Flag" in patients with systemic sclerosis. J Rheumatol 2002, 29:2666-2667.
235. Rho Y.H., Choi S.J., Lee Y.H., Ji J.D., Song G.G. Scleroderma associated with ANCA-associated vasculitis. Rheumatol Int 2006, 26:369-375.
236. Arad U., Balbir-Gurman A., Doenyas-Barak K., Amit-Vazina M., Caspi D., Elkayam O. Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum 2011, 41:223-229.
237. Wong M., Ranganath V.K., Clements P.J. Antineutrophil cytoplasmic antibody-positive digital necrosis in a patient with limited systemic sclerosis. J Rheumatol 2010, 37:214-215.
238. Bartoloni B.E., Giordano A., Luccioli F., Alunno A., Gerli R. Crescentic glomerulonephritis and circulating antineutrophil cytoplasmic antibodies in scleroderma: a case report and review of the literature. Clin Exp Rheumatol 2009, 27:385-386.
239. Marie I., Jouen F., Hellot M.F., Levesque H. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 2008, 158:141-144.
240. Schoenroth L., Fritzler M., Lonzetti L., Senecal J.L. Antibodies to beta2 glycoprotein I and cardiolipin in SSc. Ann Rheum Dis 2002, 61:183-184.
241. 2-GPI) in systemic sclerosis. Clin Exp Immunol 1996, 105:475-479.
242. Boin F., Franchini S., Colantuoni E., Rosen A., Wigley F.M., Casciola-Rosen L. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum 2009, 60:2480-2489.
243. Chun W.H., Bang D., Lee S.K. Antiphospholipid syndrome associated with progressive systemic sclerosis. J Dermatol 1996, 23:347-351.
244. Chung L., Flyckt R.L., Colon I., Shah A.A., Druzin M., Chakravarty E.F. Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. Lupus 2006, 15:595-599.
245. Moser J.J., Fritzler M.J. Cytoplasmic ribonucleoprotein (RNP) bodies and their relationship to GW/P bodies. Int J Biochem Cell Biol 2010, 42:828-843.
246. Jakymiw A., Pauley K.M., Li S., Ikeda K., Lian S., Eystathioy T., et al. The role of GW/P bodies in RNA processing and silencing. J Cell Sci 2007, 120:1317-1323.
247. Bhanji R., Eystathioy T., Chan E.K.L., Bloch D.B., Fritzler M.J. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 2007, 123:247-256.
248. Stinton L.M., Swain M., Myers R.P., Shaheen A.A., Fritzler M.J. Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clin Exp Immunol 2010, 163:147-156.
249. Li F., Ling X. Survivin study: an update of "what is the next wave"?. J Cell Physiol 2006, 208:476-486.
250. Musacchio A. Molecular biology. Surfing chromosomes (and Survivin). Science 2010, 330:183-184.
251. Casiano C.A., Martin S.J., Green D.R., Tan E.M. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996, 184:765-770.
252. Rohayem J., Diestelkoetter P., Weigle B., Oehmichen A., Schmitz M., Mehlhorn J., et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000, 60:1815-1817.
253. Yagihashi A., Ohmura T., Asanuma K., Kobayashi D., Tsuji N., Torigoe T., et al. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 2005, 362:125-130.
254. Koike Y., Muroi E., Yoshizaki A., Ogawa F., Yanaba K., Takenaka M., et al. Autoantibody against survivin in patients with systemic sclerosis. J Rheumatol 2010, 37:1864-1870.
255. Sperandio M., Gleissner C.A., Ley K. Glycosylation in immune cell trafficking. Immunol Rev 2009, 230:97-113.
256. Grader-Beck T., Boin F., von Gunten S., Smith D., Rosen A., Bochner B.S. Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease. Ann Rheum Dis 2011, 70:2218-2224.
257. Riemekasten G., Philippe A., Nather M., Slowinski T., Muller D.N., Heidecke H., et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2010, 70:530-536.
258. Iaccarino L., Ghirardello A., Canova M., Zen M., Bettio S., Nalotto L., et al. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev 2011, 10:553-558.
259. Andree H.A., Stuart M.C., Hermens W.T., Reutelingsperger C.P., Hemker H.C., Frederik P.M., et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992, 267:17907-17912.
260. Esposito G., Tamby M.C., Chanseaud Y., Servettaz A., Guillevin L., Mouthon L. Anti-annexin V antibodies: are they prothrombotic?. Autoimmun Rev 2005, 4:55-60.
261. Habeeb R.A., Mansour H.E., Abdeldayem A.M., Abo-Shady R.A., Hassan I.A., Saafan N.K., et al. Anti-annexin v antibodies: association with vascular involvement and disease outcome in patients with systemic sclerosis. Clin Med Insights Arthritis Musculoskelet Disord 2010, 3:15-23. [15-23].
262. Bona C., Saito S. Fibrillin-1 protein in tight skin mice and scleroderma. Clin Rev Allergy Immunol 2000, 18:119-126.
263. Xu H., Zaidi M., Struve J., Jones D.W., Krolikowski J.G., Nandedkar S., et al. Abnormal fibrillin-1 expression and chronic oxidative stress mediate endothelial mesenchymal transition in a murine model of systemic sclerosis. Am J Physiol Cell Physiol 2011, 300:C550-C556.
264. Tan F.K., Arnett F.C., Reveille J.D., Ahn C., Antohi S., Sasaki T., et al. Autoantibodies to fibrillin 1 in systemic sclerosis. Arthritis Rheum 2000, 43:2464-2471.
265. Wallis D.D., Tan F.K., Kielty C.M., Kimball M.D., Arnett F.C., Milewicz D.M. Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001, 44:1855-1864.
266. Tan F.K., Arnett F.C., Antohi S., Saito S., Mirarchi A., Spiera H., et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 1999, 163:1066-1072.
267. Bhattacharyya S., Wei J., Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011, 8:42-54.
268. Wipff J., Giraud M., Sibilia J., Mouthon L., Meyer O., Tiev K., et al. Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol 2008, 35:643-649.
269. Brinckmann J., Hunzelmann N., El-Hallous E., Krieg T., Sakai L.Y., Krengel S., et al. Absence of autoantibodies against correctly folded recombinant fibrillin-1 protein in systemic sclerosis patients. Arthritis Res Ther 2005, 7:R1221-R1226.
270. Wipff J., Dieude P., Avouac J., Tiev K., Hachulla E., Cracowski J.L., et al. Association of metalloproteinase gene polymorphisms with systemic sclerosis in the European Caucasian population. J Rheumatol 2010, 37:599-602.
271. Chabaud S., Corriveau M.P., Grodzicky T., Senecal J.L., Chartier S., Raymond Y., et al. Decreased secretion of MMP by non-lesional late-stage scleroderma fibroblasts after selection via activation of the apoptotic Fas-pathway. J Cell Physiol 2011, 226:1907-1914.
272. Sato S., Hayakawa I., Hasegawa M., Fujimoto M., Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003, 120:542-547.
273. Nishijima C., Hayakawa I., Matsushita T., Komura K., Hasegawa M., Takehara K., et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004, 138:357-363.
274. Morita Y., Muro Y., Sugiura K., Tomita Y. Anti-cyclic citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol 2008, 26:542-547.
275. Polimeni M., Feniman D., Skare T.S., Nisihara R.M. Anti-cyclic citrullinated peptide antibodies in scleroderma patients. Clin Rheumatol 2012, 31:877-880.
276. Ueda-Hayakawa I., Hasegawa M., Kumada S., Tanaka C., Komura K., Hamaguchi Y., et al. Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford) 2010, 49:2135-2139.
277. Santiago M., Baron M., Miyachi K., The Canadian Scleroderma Research Group, Fritzler M.J. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008, 27:77-83.
278. Wu R., Shovman O., Zhang Y., Gilburd B., Zandman-Goddard G., Shoenfeld Y. Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. Clin Rev Allergy Immunol 2007, 32:47-56.
279. Louthrenoo W., Kasitanon N., Wichainun R., Wangkaew S., Sukitawut W., Kuwata S., et al. Anti-agalactosyl IgG antibodies in Thai patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. Clin Rheumatol 2010, 29:241-246.
280. Generini S., Steiner G., Miniati I., Conforti M.L., Guiducci S., Skriner K., et al. Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. Rheumatology (Oxford) 2009, 48:920-925.
281. Kessler-Becker D., Smola S., Krieg T., Eckes B. High plasminogen activator inhibitor type 2 expression is a hallmark of scleroderma fibroblasts in vitro. Exp Dermatol 2004, 13:708-714.
282. Fritzler M.J., Hart D.A., Wilson D., Garcia-de la Torre I., Salazar-Paramo M., Vazquez-Del Mercado M., et al. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic sclerosis. J Rheumatol 1995, 22:1688-1693.
283. Rhee S.G., Chae H.Z., Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 2005, 38:1543-1552.
284. Karasawa R., Ozaki S., Nishioka K., Kato T. Autoantibodies to peroxiredoxin I and IV in patients with systemic autoimmune diseases. Microbiol Immunol 2005, 49:57-65.
285. Iwata Y., Ogawa F., Komura K., Muroi E., Hara T., Shimizu K., et al. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. Rheumatology (Oxford) 2007, 46:790-795.
286. Gugliesi F., De A.M., Mondini M., Cappello P., Giovarelli M., Shoenfeld Y., et al. The proapoptotic activity of the Interferon-inducible gene IFI16 provides new insights into its etiopathogenetic role in autoimmunity. J Autoimmun 2010, 35:114-123.
287. Seelig H.P., Ehrfeld H., Renz M. Interferon-gamma-inducible protein p16. A new target of antinuclear antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1994, 37:1672-1683.
288. Uchida K., Akita Y., Matsuo K., Fujiwara S., Nakagawa A., Kazaoka Y., et al. Identification of specific autoantigens in Sjogren's syndrome by SEREX. Immunology 2005, 116:53-63.
289. Mondini M., Vidali M., Andrea M.D., Azzimonti B., Airo P., D'Ambrosio R., et al. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum 2006, 54:3939-3944.
290. Farina G., Lafyatis D., Lemaire R., Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010, 62:580-588.